The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern’s AI platform, RADR ® , and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030 Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical... Read More